NeuroPhage Pharmaceuticals Closes $12.4M Series B Round

Cambridge-based biotech NeuroPhage secures multi-million dollar series B backing and a new biopharma investment partner, Shire LLC. Funding will advance development of Neurophage’s lead candidate NPT001 and its platform phage-based protein disaggregation technology, which holds potential for ALS therapeutic development.

Click here to read more.

Share this: